Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Mol Cancer Ther. 2019 Oct 23;19(2):564–574. doi: 10.1158/1535-7163.MCT-19-0366

Figure 3.

Figure 3.

Cer distribution and pharmacokinetics in mice. NBD Cer-RUB nanomicelles (1 mg/kg in medium; Cer-RUB) or NBD Cer-BSA complex (1 mg/kg in medium; Cer-BSA) were administered i.p. into mice (3 cases/group) bearing tumors generated by inoculation with A2780 or OVCAR-3 cancer cells. The lipids extracted from tissues at each time point were analyzed using HPLC. A, Cer levels in tissues of mice 3 h after administration. Cer-RUB or Cer-BSA was i.p.-administered into mice bearing OVCAR-3 tumors. *, p<0.001 compared to mice administered NBD Cer-BSA complex. B, HPLC chromatograms of NBD C6-Cer in OVCAR-3 tumors of mice 3 h after administrations. C, Cer levels in tissues of mice bearing A2780 tumors or OVCAR-3 tumors 3 h following administrations. D, Kinetics of C6-Cer in tissues of mice bearing OVCAR-3 tumors administrated NBD Cer-RUB nanomicelles (1 mg/kg).